Rivastigmine transdermal

Rivastigmine Transdermal (Exelon patch) Rizatriptan (Maxalt, Maxalt MLT)... [Pg.43]

Rivastigmine Transdermal (Exelon Patch) [Cholinesterase Inhibitor/Anti-Alzheimer Agent] Uses MUd/mod Alzheimer and Parkinson Dz dementia Action Acetylcholinesterase inhibitor Dose Initial 4.6-mg patch/d applied to back, chest, upper arm, T 9.5 mg after 4 wk if tolCTated Caution [ ] Sick sinus synd, conduction defects, asthma, COPD, urinary obst, Sz Contra Hypersensitivity to rivastigmine, other carbamates Disp Transdermal patch 5 cm (4.6 mg/24 h), 10 cm (9.5 mg/24 h) SE NA /D EMS See Rivastigmine OD See Rivastigmine... [Pg.277]

Lefevre, G., Pommier, F., Sedek, G., Allison, M., Huang, H.L., Kiese, B., Ho, Y.Y. and Appel-Dingemanse, S. (2008) Pharmacokinetics and bioavailahdity of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. Journal of Clinical Pharmacology, 48, 246—252. [Pg.67]

Rivastigmine transdermal patches provide a useful treatment option for patients with mild to moderate Alzheimer s disease, giving improved tolerability compared with rivastigmine capsules that provide comparable drug exposure and efficacy [105 ]. [Pg.11]

An 85-year-old woman with Alzheimer s disease started using a daily rivastigmine transdermal patch (Exelon , 4.6 mg) and after... [Pg.11]

Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer s disease. Lit J Qin Pract 2010 64 651-60. [Pg.17]

Mumoli N, Carmignani G, Luschi R, Cei M, Chiavistelli P. Hepatitis with cholestasis caused by rivastigmine transdermal patch. Am J Gastroenterol 2009 104 2859-60. [Pg.25]

Pregelj P. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer s dementia in naturalistic conditions. Psychogeriatrics 2012 12 165-71. [Pg.12]

Methylphenidate, Transdermal (Daytrana) Modafinil (Provigil) Natalizumab (Tysabri) Nimodipine (Nimotop) Rivastigmine (Exelon)... [Pg.43]

Makris M, Koulouris S, Koti I, Agglides X, Kalogiromitros D. Maculopapular eruption to rivastigmine s transdermal patch application and successful oral desensitization. AUergy 2010 65 925-6. [Pg.17]

Lamer AJ. Transdermal rivastigmine for Alzheimer s disease skin deep or scratching the surface Int J Clin Pract 2010 64 534-6. [Pg.17]

Transdermal patches registered at present are patches containing active substances such as buprenorphine, estradiol, fentanyl, glyceryl trinitrate, nicotine, oxybutynine, rivastigmine, rotigotine and scopolamine. These transdermal patches are used in the treatment of a variety of diseases. They release the active substance during a period of 24 up to 72 h, depending on the type of patch used and the active substance. After application of the patch plasma concentration slowly rises until a steady concentration is reached. [Pg.238]

Observational studies In a multicenter study of a transdermal rivastigmine patch... [Pg.17]

Liver Hepatotoxicity associated with transdermal rivastigmine use has been reported [134 ]. [Pg.18]

Drag overdose An 80-year-old woman with Alzheimer s disease had an overdose when she used nine 5 cm transdermal patches of rivastigmine She had fasciculation... [Pg.18]

Segers K, Cytryn E, Surquin M. Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine A retropro-spective, pilot study. ] Clin Psychopharmacol 2012 32(3) 412-5. [Pg.12]

Seibert ], Tracik F, Articus K, Spittler S. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer s disease in daily practice. Neuropsychiatr Dis Treat 2012 8 141-7. [Pg.12]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...